Program
rezpegaldesleukin
Also written as “LY3471851” and “Rezpegaldesleukin”.
Its studies are mostly in Dermatitis, Atopic · Lupus Erythematosus, Systemic · Alopecia Areata · Psoriasis · Colitis, Ulcerative, led by Nektar Therapeutics.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Nektar Therapeutics | 133 open or running | phase 3since Jul 2, 2026 | May 7, 2018 | May 2028phase 3 · NCT07690371 |
Also a collaborator on its studies: Eli Lilly.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 7, 2018First study: phase 1 study in Lupus Erythematosus, SystemicFirst studyNCT03556007 · 48 enrolled · United States
- Sep 5, 2019Phase 1 study in Dermatitis, AtopicNCT04081350 · 48 enrolled · United States
- Oct 7, 20192 phase 1 studiesNCT04119557, NCT04133116
- May 6, 2020Phase 1 study in HealthyNCT04380324 · 100 enrolled · United States
- Jun 15, 2020Phase 2 study in Lupus Erythematosus, SystemicNCT04433585 · 291 enrolled · United States, Argentina, Australia and more
- Dec 8, 2020Phase 2 study in Colitis, UlcerativeNCT04677179 · 81 enrolled · United States, Argentina, Australia and more
- Aug 9, 2021Phase 1 study in HealthyNCT04998487 · 71 enrolled · United States
- Oct 3, 2022Phase 1 study in HealthyNCT05565729 · 41 enrolled · United States
- Nov 13, 2023Phase 2 study in Moderate to Severe Atopic DermatitisNCT06136741 · 396 enrolled · United States, Australia, Bulgaria and more
- Mar 25, 2024Phase 2 study in Alopecia AreataNCT06340360 · 94 enrolled · United States, Canada, Poland
- Jul 2, 20262 phase 3 studies in Moderate-to-Severe Atopic DermatitisPhase 3 reachedNCT07690371, NCT07711418
Ahead
- May 2028Primary completion: phase 3 study in Moderate-to-Severe Atopic DermatitisNCT07690371
- Jun 2028Primary completion: phase 3 study in Moderate-to-Severe Atopic DermatitisNCT07711418
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07711418Moderate-to-Severe Atopic Dermatitis · United States | 3 | Recruiting | Jun 2028 | 510 |
| NCT07690371Moderate-to-Severe Atopic Dermatitis · United States | 3 | Recruiting | May 2028 | 510 |
| NCT06340360Alopecia Areata · United States, Canada, Poland | 2 | Completed | Nov 26, 2025 | 94 |
| NCT06136741Moderate to Severe Atopic Dermatitis · United States, Australia, Bulgaria and more | 2 | Active, not recruiting | May 6, 2025 | 396 |
| NCT05565729Healthy · United States | 1 | Completed | Feb 23, 2023 | 41 |
| NCT04998487Healthy · United States | 1 | Completed | Jul 6, 2022 | 71 |
| NCT04677179Colitis, Ulcerative · United States, Argentina, Australia and more | 2 | Terminated | Aug 9, 2022 | 81 |
| NCT04433585Lupus Erythematosus, Systemic · United States, Argentina, Australia and more | 2 | Completed | Jan 10, 2023 | 291 |
| NCT04380324Healthy · United States | 1 | Completed | Jan 20, 2019 | 100 |
| NCT04133116Healthy · United States | 1 | Completed | Mar 6, 2020 | 36 |
| NCT04119557Psoriasis · United States | 1 | Completed | Jul 21, 2021 | 30 |
| NCT04081350Dermatitis, Atopic · United States | 1 | Completed | Jun 24, 2022 | 48 |
| NCT03556007Lupus Erythematosus, Systemic · United States | 1 | Completed | Aug 29, 2019 | 48 |
How it is read
Names in the registry
- “LY3471851”, 9 entries
- “Rezpegaldesleukin”, 4 entries
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 4 studies
- Lupus Erythematosus, Systemic, 2 studies
- Alopecia Areata, 1 study
- Psoriasis, 1 study
- Colitis, Ulcerative, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.